Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GANX 
Gain Therapeutics Inc (GANX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GANX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.71
1 Year Target Price $7.71
| 3 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.29% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 67.58M USD | Price to earnings Ratio - | 1Y Target Price 7.71 |
Price to earnings Ratio - | 1Y Target Price 7.71 | ||
Volume (30-day avg) 7 | Beta 0.11 | 52 Weeks Range 0.95 - 3.19 | Updated Date 08/29/2025 |
52 Weeks Range 0.95 - 3.19 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.17 | Actual -0.19 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -74.31% | Return on Equity (TTM) -240.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 61569881 | Price to Sales(TTM) 255.5 |
Enterprise Value 61569881 | Price to Sales(TTM) 255.5 | ||
Enterprise Value to Revenue 138.33 | Enterprise Value to EBITDA -1.55 | Shares Outstanding 35948600 | Shares Floating 29579855 |
Shares Outstanding 35948600 | Shares Floating 29579855 | ||
Percent Insiders 3.64 | Percent Institutions 10.56 |
Upturn AI SWOT
Gain Therapeutics Inc
Company Overview
History and Background
Gain Therapeutics, Inc. was founded in 2017. It is focused on discovering and developing novel therapies to treat diseases caused by protein misfolding, particularly neurodegenerative diseases and lysosomal storage disorders. The company's initial focus was on leveraging its proprietary SEE-Txu2122 platform to identify allosteric modulators of enzymes.
Core Business Areas
- Drug Discovery and Development: Gain Therapeutics focuses on discovering and developing small molecule therapeutics that target misfolded proteins. Their proprietary SEE-Tx platform is central to this process, identifying allosteric binding sites and developing molecules that can restore proper protein folding.
- Neurodegenerative Diseases: Gain Therapeutics targets neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, where protein misfolding plays a significant role in disease pathology.
- Lysosomal Storage Disorders: Gain Therapeutics is also developing therapies for lysosomal storage disorders, which are genetic diseases caused by enzyme deficiencies leading to the accumulation of undigested material within lysosomes.
Leadership and Structure
Gain Therapeutics is led by CEO Matthias Alder, PhD. The company has a scientific advisory board composed of experts in protein folding, neurodegenerative diseases, and drug development. The organizational structure includes departments focused on research and development, clinical development, and corporate operations.
Top Products and Market Share
Key Offerings
- GT-02287 (GBA1 Parkinson's Disease): GT-02287 is Gain's lead drug candidate, targeting misfolded GBA1 in Parkinson's disease. It's designed to restore GBA1 enzyme activity. Currently in Phase 1 clinical trials. Market share is currently 0, as it is in development. Competitors targeting GBA1 include Denali Therapeutics (DNLI) and Prevail Therapeutics (acquired by Eli Lilly, LLY). The market for Parkinson's disease therapeutics is substantial, estimated at billions of dollars annually.
- GT-02329 (GCase in Neuronopathic Gaucher Disease (nGD)): GT-02329 is designed to restore the function of mutant glucocerebrosidase (GCase). It is designed to treat severe forms of the lysosomal storage disorder. Market share is currently 0, as it is in development. Competitors include Sanofi (SNY) and Takeda (TAK). The market for Gaucher Disease therapeutics is estimated at several billion dollars.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The focus on precision medicine and targeted therapies is increasing, driven by advances in genomics and proteomics.
Positioning
Gain Therapeutics is a clinical-stage biopharmaceutical company focused on allosteric modulators for misfolded protein diseases. Its SEE-Tx platform is a key differentiator, providing a potential advantage in identifying novel drug candidates. The company is targeting niche markets with high unmet needs.
Total Addressable Market (TAM)
The TAM for neurodegenerative diseases and lysosomal storage disorders is estimated at several billion dollars annually. Gain Therapeutics is positioned to capture a portion of this market by developing disease-modifying therapies that address the underlying causes of these conditions.
Upturn SWOT Analysis
Strengths
- Proprietary SEE-Tx platform for drug discovery
- Targeting unmet needs in neurodegenerative and lysosomal storage disorders
- Experienced management team
- Focus on disease-modifying therapies
Weaknesses
- Early stage of development, high risk of clinical trial failure
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful development and commercialization of lead drug candidates
- Reliance on intellectual property protection
Opportunities
- Positive clinical trial results could lead to significant market value increase
- Partnerships with larger pharmaceutical companies for development and commercialization
- Expansion of pipeline to address additional protein misfolding diseases
- Advancements in understanding of disease mechanisms
Threats
- Clinical trial failures
- Competition from other companies developing therapies for similar diseases
- Regulatory hurdles
- Changes in reimbursement policies
- Patent challenges
Competitors and Market Share
Key Competitors
- Denali Therapeutics (DNLI)
- Sanofi (SNY)
- Takeda (TAK)
- Eli Lilly (LLY)
Competitive Landscape
Gain Therapeutics faces competition from established pharmaceutical companies with greater resources and experience. Its competitive advantage lies in its SEE-Tx platform and focus on specific protein misfolding diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily in R&D spending and expansion of clinical programs.
Future Projections: Future growth depends on successful clinical trial outcomes and potential partnerships. Analysts project potential revenue generation upon successful commercialization of lead drug candidates. It is impossible to know without the Phase 2 and 3 clinical results.
Recent Initiatives: Recent initiatives include advancement of GT-02287 into Phase 1 clinical trials and continued preclinical development of other pipeline programs.
Summary
Gain Therapeutics is a high-risk, high-reward clinical-stage company focused on innovative therapies for protein misfolding diseases. The company's SEE-Tx platform offers a potential advantage, but its success hinges on clinical trial outcomes. Investors should be aware of the significant risks involved, particularly the potential for clinical trial failures and competition from larger pharmaceutical companies. The company's recent initiation of Phase 1 trials for GT-02287 is a positive development, but it is crucial to monitor the trial's progress and potential for strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share estimations are approximate, especially given the R&D focus of this company, and should not be considered precise. Investment decisions should be made based on independent research and consultation with a qualified financial advisor. The competitive landscape and TAM data are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gain Therapeutics Inc
Exchange NASDAQ | Headquaters Bethesda, MD, United States | ||
IPO Launch date 2021-03-18 | President, CEO & Director Mr. Gene Mack M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://gaintherapeutics.com |
Full time employees 23 | Website https://gaintherapeutics.com | ||
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.